Cargando…

Synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against Klebsiella and Pseudomonas.

Fifty-three clinical isolates of Klebsiella and fifty-one clinical isolates of Pseudomonas aeruginosa, twenty-six of which were carbenicillin-(CARB) resistant, were tested for susceptibility to mezlocillin (MEZ), azlocillin (AZL), and piperacillin (PIP), both alone and in combination with tobramycin...

Descripción completa

Detalles Bibliográficos
Autores principales: Downs, J. T., Andriole, V. T., Ryan, J. L.
Formato: Texto
Lenguaje:English
Publicado: Yale Journal of Biology and Medicine 1986
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2590060/
https://www.ncbi.nlm.nih.gov/pubmed/3634545
_version_ 1782161241230278656
author Downs, J. T.
Andriole, V. T.
Ryan, J. L.
author_facet Downs, J. T.
Andriole, V. T.
Ryan, J. L.
author_sort Downs, J. T.
collection PubMed
description Fifty-three clinical isolates of Klebsiella and fifty-one clinical isolates of Pseudomonas aeruginosa, twenty-six of which were carbenicillin-(CARB) resistant, were tested for susceptibility to mezlocillin (MEZ), azlocillin (AZL), and piperacillin (PIP), both alone and in combination with tobramycin (TOB) using the microtiter broth diluent method and an inoculum density of 10(6) CFU/ml. The Klebsiella were highly resistant to TOB, MEZ, and PIP (MIC90: 8, greater than 256, greater than 128 micrograms/ml, respectively). Synergy was demonstrated in 53 percent (PIP/TOB) and 51 percent (MEZ/TOB). An indifferent response was observed in 47 percent (PIP/TOB) and 49 percent MEZ/TOB of the Klebsiella. PIP, MEZ, and AZL in combination with TOB showed synergism against CARB-resistant Pseudomonas in less than 10 percent of the strains tested. Synergy could be demonstrated against CARB-susceptible Pseudomonas with the combinations PIP/TOB, AZL/TOB, and MEZ/TOB in 12 percent, 12 percent, and 24 percent, respectively, of the twenty-five strains tested. Indifferent effects were observed in 84 percent, 88 percent, and 76 percent, respectively, of these same CARB-susceptible strains. These data suggest that there is no significant difference in the incidence of synergy with these new penicillins and tobramycin against either Pseudomonas or Klebsiella.
format Text
id pubmed-2590060
institution National Center for Biotechnology Information
language English
publishDate 1986
publisher Yale Journal of Biology and Medicine
record_format MEDLINE/PubMed
spelling pubmed-25900602008-11-28 Synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against Klebsiella and Pseudomonas. Downs, J. T. Andriole, V. T. Ryan, J. L. Yale J Biol Med Research Article Fifty-three clinical isolates of Klebsiella and fifty-one clinical isolates of Pseudomonas aeruginosa, twenty-six of which were carbenicillin-(CARB) resistant, were tested for susceptibility to mezlocillin (MEZ), azlocillin (AZL), and piperacillin (PIP), both alone and in combination with tobramycin (TOB) using the microtiter broth diluent method and an inoculum density of 10(6) CFU/ml. The Klebsiella were highly resistant to TOB, MEZ, and PIP (MIC90: 8, greater than 256, greater than 128 micrograms/ml, respectively). Synergy was demonstrated in 53 percent (PIP/TOB) and 51 percent (MEZ/TOB). An indifferent response was observed in 47 percent (PIP/TOB) and 49 percent MEZ/TOB of the Klebsiella. PIP, MEZ, and AZL in combination with TOB showed synergism against CARB-resistant Pseudomonas in less than 10 percent of the strains tested. Synergy could be demonstrated against CARB-susceptible Pseudomonas with the combinations PIP/TOB, AZL/TOB, and MEZ/TOB in 12 percent, 12 percent, and 24 percent, respectively, of the twenty-five strains tested. Indifferent effects were observed in 84 percent, 88 percent, and 76 percent, respectively, of these same CARB-susceptible strains. These data suggest that there is no significant difference in the incidence of synergy with these new penicillins and tobramycin against either Pseudomonas or Klebsiella. Yale Journal of Biology and Medicine 1986 /pmc/articles/PMC2590060/ /pubmed/3634545 Text en
spellingShingle Research Article
Downs, J. T.
Andriole, V. T.
Ryan, J. L.
Synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against Klebsiella and Pseudomonas.
title Synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against Klebsiella and Pseudomonas.
title_full Synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against Klebsiella and Pseudomonas.
title_fullStr Synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against Klebsiella and Pseudomonas.
title_full_unstemmed Synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against Klebsiella and Pseudomonas.
title_short Synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against Klebsiella and Pseudomonas.
title_sort synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against klebsiella and pseudomonas.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2590060/
https://www.ncbi.nlm.nih.gov/pubmed/3634545
work_keys_str_mv AT downsjt synergismofazlocillinmezlocillinpiperacillinincombinationwithtobramycinagainstklebsiellaandpseudomonas
AT andriolevt synergismofazlocillinmezlocillinpiperacillinincombinationwithtobramycinagainstklebsiellaandpseudomonas
AT ryanjl synergismofazlocillinmezlocillinpiperacillinincombinationwithtobramycinagainstklebsiellaandpseudomonas